Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide

Project description

Oncogene targeting for cancer suicide

Cancer development and progression is often driven by oncogenic transcription factors (OTFs) which disrupt normal cellular process and cause uncontrolled cell division. OTFs are formed through genetic abnormalities or chromosomal translocations and have served as targets for therapeutic interventions. However, the unique structural and functional characteristics of certain OTFs render them undruggable. Funded by the European Research Council, the Cancer-Harakiri project aims to address this issue by leveraging the unique DNA-binding preferences of OTFs for a novel therapeutic strategy. The idea is to delineate the regulatory landscape of OTFs and identify genes that regulate their activity. The ultimate goal is to induce cancer cell suicide.

Objective

Many aggressive cancers, such as pediatric high-risk Ewing sarcoma and alveolar rhabdomyosarcoma, are fueled by and addicted to chimeric oncogenic transcription factors (OTFs). So far, all attempts to suppress these potent OTFs largely failed, wherefore they are classified as undruggable.
This proposal challenges this dogma with a novel strategy to leverage, rather than to suppress, the exquisite neomorphic DNA-binding preferences of OTFs to express therapeutic genes specifically in cancer cells. In pursuing three ambitious aims, this project goes far beyond an original proof-of-concept study in which we drove pediatric cancer cells in preclinical models into suicide (CANCER-HARAKIRI) via viral transfer of therapeutic genes induced by the specific interaction of an OTF with its neomorphic DNA-binding motif:
In Aim 1, we will genetically engineer and functionally test a conceptionally advanced viral vector in vivo with optimized general design, oncotropism, and therapeutic payload focusing on immuno-oncological aspects.
In Aim 2, we will comprehensively map the regulome of OTFs using novel reporter cell lines, single-cell sequencing, RNAi-screens, and CRISPR interference to identify and validate OTF-inhibiting genes that can be co-targeted in our vector to prevent escape variants with low OTF-activity.
In Aim 3, we will integrate insights from Aims 1&2 into our new vector design, translate our therapeutic approach from our main model entity, Ewing sarcoma, to other OTF-driven cancers, and set the stage for GMP-compliant virus production and initiation of a clinical trial.
This integrative approach combines expertise and technology across disciplines with original experimental tools to afford a comprehensive understanding of the OTF-regulome, and to rationally design and leap ahead an innovative therapeutic concept, which has the potential to revolutionize the therapy of metastatic OTF-driven cancers. Thus, we will exploit the undruggable to promote CANCER-HARAKIRI.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 1 992 235,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 1 992 235,00

Beneficiaries (1)